J&J Gains Most Since January After Hiking Annual Profit Forecast
- Strong sales increases in pharma, med-tech sales drive results
- Covid booster shot under consideration by U.S. regulators
This article is for subscribers only.
Johnson & Johnson gained the most in almost nine months after raising its 2021 profit forecast, with strong performance across the health-care giant’s main divisions driving quarterly results.
Adjusted earnings for the year will be $9.77 to $9.82 a share, J&J said Tuesday in a statement, up from the previous guidance of $9.60 to $9.70. Third-quarter adjusted earnings per share were $2.60, J&J said, beating Wall Street’s average estimate of $2.36.